PubRank

Robert J Lutz

Author PubWeight™ 28.32‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008 5.34
2 The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res 2009 2.25
3 Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 2006 1.67
4 A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood 2013 1.56
5 Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 2006 1.29
6 A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp Eye Res 2005 1.18
7 Transport barriers in transscleral drug delivery for retinal diseases. Ophthalmic Res 2007 1.17
8 Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging. Invest Ophthalmol Vis Sci 2004 1.17
9 Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res 2002 1.15
10 SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res 2011 1.14
11 Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res 2010 1.11
12 Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration. Retina 2006 1.08
13 Assessment of subconjunctival and intrascleral drug delivery to the posterior segment using dynamic contrast-enhanced magnetic resonance imaging. Invest Ophthalmol Vis Sci 2007 1.02
14 Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjug Chem 2011 1.01
15 Drug elimination kinetics following subconjunctival injection using dynamic contrast-enhanced magnetic resonance imaging. Pharm Res 2007 0.91
16 Study of ocular transport of drugs released from an intravitreal implant using magnetic resonance imaging. Ann Biomed Eng 2005 0.90
17 The pharmacokinetics of rituximab following an intravitreal injection. Exp Eye Res 2005 0.88
18 Evaluation of coupled convective-diffusive transport of drugs administered by intravitreal injection and controlled release implant. J Control Release 2005 0.85
19 Alphav integrin-targeted immunoconjugates regress established human tumors in xenograft models. Clin Cancer Res 2007 0.82
20 Preclinical evaluation of a novel episcleral cyclosporine implant for ocular graft-versus-host disease. Invest Ophthalmol Vis Sci 2005 0.79
21 Erythrocyte survival is promoted by plasma and suppressed by a Bak-derived BH3 peptide that interacts with membrane-associated Bcl-X(L). Blood 2002 0.78
22 Sustained subconjunctival protein delivery using a thermosetting gel delivery system. J Ocul Pharmacol Ther 2010 0.77
23 Estimation of the differential pressure at renal artery stenoses. Magn Reson Med 2004 0.75